
A Bloomberg article titled, 'Heroin, Nazis, and Agent Orange: Inside the $66 Billion Merger of the Year,' didn't help.
People familiar with internal discussions at Bayer said the aspirin inventor is considering the name change to avoid sullying its reputation. They also said no decision has been made yet, and Bayer's managers could have some time to think it over.
Following the purchase agreement, Bayer CEO Werner Baumann said there's an opportunity for the companies to jointly "get beyond this image and reputation thing" by building on the trust Bayer enjoys in Europe. In May the drug maker was named the world's most reputable pharmaceutical brand by the Reputation Institute.
The $66 billion acquisition deal, which is now being closely scrutinized by antitrust regulators, is expected to be completed by the end of 2017. If the deal goes through it will make Bayer the world's biggest seed and pesticide producer.













Comment: See also: